Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: X
National Institutes of Health (NIH) Director Dr. Jay Bhattacharya has urged parents to vaccinate their children against measles, saying, “I trust the science,” as the United States faces its worst measles surge in decades.
Speaking to CBS News’ Face the Nation on August 9, Bhattacharya said vaccination remains the best way to protect children from the highly contagious disease.
“If you want to protect your kids from these sort of preventable diseases, yes, you should vaccinate your kids,” Bhattacharya said. He added that he has been “very, very clear” about recommending measles vaccination.
His comments come as the US has recorded 2,465 confirmed measles cases in 2026 as of August 6, according to the Centers for Disease Control and Prevention (CDC).
The figure has already surpassed the total reported in 2025 and represents the highest annual case count in the country in about 35 years.
Also read: CDC Recommends All International Travelers To Get Measles Vaccine
Bhattacharya pointed to declining public trust in health institutions as one factor behind the resurgence.
“There’s been a lot of outbreaks, not just the United States, but around the world,” he said. “A lot of that has to do with sort of a collapse in public trust in a lot of science.”
The CDC says only 10 US states had measles vaccination coverage above the approximately 95% level needed to maintain community protection during the previous school year.
The growing outbreak has raised another concern, which is whether the US could lose its measles elimination status.
Experts have warned that continued transmission could jeopardize the status the country has maintained since 2000.
A recent analysis described losing elimination status in 2026 as highly likely unless vaccination coverage improves and ongoing transmission is interrupted.
For parents, the message from the NIH chief is straightforward: the measles vaccine remains the scientific evidence-backed way to protect children. “I trust the science,” Bhattacharya said.
Also read: Dr. Erica Schwartz Confirmed As CDC’s First Permanent Director In Nearly A Year
Bhattacharya also addressed concerns about children returning to school while measles is circulating.
“It is even more important that these kids go to school,” he said, warning against creating fear around unvaccinated children.
“That’s a tremendous mistake,” Bhattacharya said, arguing that parents should vaccinate their children rather than fear school attendance.
His comments are notable amid renewed debate over childhood vaccines under Health Secretary Robert F. Kennedy Jr., who has a long history of vaccine skepticism but recently also urged parents to vaccinate children against measles.
The measles, mumps and rubella (MMR) vaccine remains one of the strongest tools against measles. Two doses are about 97% effective at preventing measles, while one dose provides about 93% protection.
That protection becomes particularly important in schools and communities because measles spreads extremely easily. When vaccination rates fall below the level needed for herd immunity, the virus can move rapidly through pockets of susceptible people.
Credit: AI
The U.S. Department of Agriculture (USDA) has issued a new public health alert for 18 meat and poultry products that contain recalled jalapeño peppers potentially contaminated with Salmonella, expanding the food-safety concerns surrounding an outbreak in multiple states in the US.
The products were made using jalapeños that had already been recalled by the U.S. Food and Drug Administration (FDA). Many of the affected products are sold under brands including Taylor Farms, Walmart’s Marketside and H-E-B. The products have expiry dates extending through August 15.
The USDA’s Food Safety and Inspection Service (FSIS) said the issue came to light after the FDA notified the agency that several meat and poultry establishments had received the recalled jalapeños as an ingredient.
The agency warned that some of the products may still be sitting in consumers’ refrigerators or freezers, advising people not to eat them. Retailers have also been told not to sell the affected products.
The latest alert is part of a much larger Salmonella investigation. According to the FDA and CDC, the outbreak involves Salmonella Javiana linked to fresh jalapeños grown in Sinaloa, Mexico, and distributed in the US by Coast Citrus Distributors.
As of August 5, 345 people across 27 states had been infected, with 36 hospitalizations and no reported deaths. The outbreak began between June 19 and July 20.
Investigators found that 177 of 191 interviewed patients, or 93%, had eaten at a Mexican-style restaurant before becoming sick. This included people who had eaten at Chipotle and QDOBA locations.
The FDA's investigation identified a common grower in Sinaloa as the most likely source. Coast Citrus has agreed to recall the remaining implicated peppers and has stopped importing from that grower.
Also read: Maharashtra Becomes Second Indian State To Ban Sale Of Fake Paneer: Here's Why It Can Be Harmful
This case highlights how a contaminated ingredient can move through the food supply chain and end up in products that are not immediately connected to the outbreak.
While the FDA regulates most fresh produce, the USDA's FSIS oversees federally regulated meat and poultry products.
Once contaminated jalapeños were used as ingredients in meat and poultry products, the issue crossed into USDA-regulated food.
Also read: Nearly 1.6 Million Dozen Eggs Recalled in US Over Potential Salmonella Contamination: FDA
Young children, older adults and people with weakened immune systems are at greater risk of developing severe illness.
Most importantly, contaminated food may look, smell and taste completely normal, meaning consumers cannot rely on appearance or taste to determine whether the food is safe.
Consumers who have purchased products covered by the USDA alert should not eat them. They should either discard them away or return them to the place of purchase.
Anyone who develops symptoms after eating a potentially contaminated product should contact a healthcare provider and disclose the possible Salmonella exposure.
Credit: AI
Artificial intelligence has taken another step forward in biology. Scientists have created viruses designed by AI and shown that they can work in the laboratory, showing promise for new treatments. But this has also triggered concerns about biosecurity.
The viruses are bacteriophages, or viruses that infect bacteria rather than humans. Researchers led by Dr Brian Hie, a chemical engineer at Stanford University, used AI models called Evo1 and Evo2 to design functioning genomes for these viruses. The models were trained using genetic data from around 2 million bacteriophages.
The researchers generated thousands of potential viral genomes and selected nearly 300 to manufacture and test in the laboratory. Only 16 ultimately proved viable.
However, a combination of the AI-designed viruses was able to kill two strains of E coli that had developed resistance to naturally occurring bacteriophages.
The technology works like the large language models behind AI chatbots, but instead of learning patterns in human language, genome language models learn patterns in genetic sequences.
The AI was able to generate genetic instructions for new bacteriophages, which were then produced in the laboratory and tested against bacteria.
This matters because bacteriophages are already being explored as a treatment for persistent bacterial infections.
If scientists can rapidly design viruses that target specific bacteria and overcome resistance, the approach could strengthen phage therapy, particularly as antibiotic resistance continues to complicate treatment.
The researchers said the ability to rapidly design genomes and adapt them to particular bacteria could “transform phage therapy” and expand biotechnology.
The viruses created in this experiment were designed to infect bacteria. The researchers also deliberately excluded genetic information from viruses that infect humans, animals and plants from the AI's training data, reducing the chance of the system generating dangerous pathogens.
But the experiment demonstrates something bigger: AI can now produce functioning viral genomes.
That raises questions about what could happen if similar technology were trained on genetic information from harmful pathogens.
Prof Tom Inglesby and Dr Moritz Hanke of the Center for Health Security at Johns Hopkins University warned that the ability to create viral genomes using generative AI now exists, but the systems and regulations needed to govern the AI have not caught up.
They warned that genomes designed for human, animal or plant pathogens could potentially generate new threats that existing measures may not be equipped to contain.
Also read: The Rise of Robotic Joint Replacement: How Technology Is Transforming Orthopaedic Surgery
Tom Ellis, a professor of synthetic genome engineering at Imperial College London, said the experiment was impressive but pointed out that bacteriophages have extremely small and relatively simple genomes.
He also argued that fears surrounding fully AI-designed pathogens may currently be overstated. He said that modifying existing pathogens to make them more dangerous remains a much easier and more immediate concern.
Dr Filippa Lentzos of King's College London said the solution should not focus only on AI. Instead, safeguards should extend across the entire process, including AI development and access, research, DNA synthesis screening and lab biosafety.
© 2024 Bennett, Coleman & Company Limited